Infections transmitted by transplantation

Infectious Disease Clinics of North America

Volumn 24, Issue 2, 2010, Pages 497-514

  Morris, Michele I ^a   Fischer, Staci A ^b   Ison, Michael G ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b BROWN UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Donor screening; Donor derived infection; Organ transplant; Transmission

Indexed keywords

ANTIVIRUS AGENT; BENZNIDAZOLE; COTRIMOXAZOLE; FLUCONAZOLE; HEPATITIS B ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; NIFURTIMOX;

ASSAY; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; CADAVER DONOR; CHAGAS DISEASE; COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ENDEMIC DISEASE; FLAVIVIRUS INFECTION; FUNGUS TRANSMISSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; LABORATORY TEST; LIVING DONOR; MYCOBACTERIUM TUBERCULOSIS; MYCOSIS; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PARASITE TRANSMISSION; PARASITOSIS; PRACTICE GUIDELINE; REVIEW; RISK MANAGEMENT; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SEROLOGY; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; TISSUE TRANSPLANTATION; TOXOPLASMA GONDII; TOXOPLASMOSIS; TRANSPLANTATION; TUBERCULOSIS; VIRUS INFECTION; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

CYTOMEGALOVIRUS INFECTIONS; DISEASE TRANSMISSION, INFECTIOUS; DONOR SELECTION; EPSTEIN-BARR VIRUS INFECTIONS; HEPATITIS C; HIV INFECTIONS; HUMANS; IATROGENIC DISEASE; ORGAN TRANSPLANTATION; STEM CELL TRANSPLANTATION; TOXOPLASMOSIS;

EID: 77952708254     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.02.002     Document Type: Review

References (91)

1. Ahn J., Cohen S.M. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl 2008, 14(11):1603-1608.
2. Bowen P.A., Lobel S.A., Caruana R.J., et al. Transmission of human immunodeficiency virus (HIV) by transplantation: clinical aspects and time course analysis of viral antigenemia and antibody production. Ann Intern Med 1988, 108(1):46-48.
3. Calabrese F., Angelini A., Cecchetto A., et al. HIV infection in the first heart transplantation in Italy: fatal outcome. Case report. APMIS 1998, 106(4):470-474.
4. Fischer S.A., Graham M.B., Kuehnert M.J., et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 2006, 354(21):2235-2249.
5. Iwamoto M., Jernigan D.B., Guasch A., et al. Transmission of West Nile virus from an organ donor to four transplant recipients. N Engl J Med 2003, 348(22):2196-2203.
6. Limaye A.P., Connolly P.A., Sagar M., et al. Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med 2000, 343(16):1163-1166.
7. Lumbreras C., Sanz F., Gonzalez A., et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. Clin Infect Dis 2001, 33(5):722-726.
8. Palacios G., Druce J., Du L., et al. A new arenavirus in a cluster of fatal transplant-associated diseases. N Engl J Med 2008, 358(10):991-998.
9. Srinivasan A., Burton E.C., Kuehnert M.J., et al. Transmission of rabies virus from an organ donor to four transplant recipients. N Engl J Med 2005, 352(11):1103-1111.
10. Ison M.G., Hager J., Blumberg E., et al. Donor-derived disease transmission events in the United States: data reviewed by the OPTN/UNOS Disease Transmission Advisory Committee. Am J Transplant 2009, 9(8):1929-1935.
11. Lumbreras C. Bacterial pathogens and donor transmission. 3rd International Transplant Infectious Diseases Conference. Prague (Czech Republic), 2007.
12. Transplantation-transmitted tuberculosis-Oklahoma and Texas, 2007. MMWR Morb Mortal Wkly Rep 2008, 57(13):333-336.
13. Fishman J.A., Strong D.M., Kuehnert M.J. Organ and tissue safety workshop 2007: advances and challenges. Cell Tissue Bank 2009, 10(3):271-280.
14. 2.0 Minimum procurement standards for an organ procurement organization (OPO) Available at:, Accessed March 15, 2010. http://www.unos.org/PoliciesandBylaws2/policies/pdfs/policy_2.pdf.
15. 4.0 Acquired Immune Deficiency Syndrome (AIDS), human pituitary derived growth hormone (HPDGH), and reporting of potential recipient diseases or medical conditions, including malignancies, of donor origin Available at:, Accessed March 15, 2010. http://www.unos.org/PoliciesandBylaws2/policies/pdfs/policy_16.pdf.
16. Glynn S.A., Wright D.J., Kleinman S.H., et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005, 45(6):994-1002.
17. Fiebig E.W., Wright D.J., Rawal B.D., et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17(13):1871-1879.
18. Biswas R., Tabor E., Hsia C.C., et al. Comparative sensitivity of HBV NATs and HBSAG assays for detection of acute HBV infection. Transfusion 2003, 43(6):788-798.
19. Busch M.P., Glynn S.A., Stramer S.L., et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005, 45(2):254-264.
20. Schreiber G.B., Busch M.P., Kleinman S.H., et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996, 334(26):1685-1690.
21. Kleinman S., Busch M.P., Korelitz J.J., et al. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997, 11(3):155-172.
22. Dodd R.Y., Notari EPt, Stramer S.L. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002, 42(8):975-979.
23. Nucleic acid testing (NAT) for human immunodeficiency virus type 1 (HIV-1) and hepatitis C (HCV): testing, product disposition, and donor deferral and reentry Available at:, Accessed March 15, 2010. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm080278.pdf.
24. Challine D., Pellegrin B., Bouvier-Alias M., et al. HIV and hepatitis C virus RNA in seronegative organ and tissue donors. Lancet 2004, 364(9445):1611-1612.
25. Yao F., Seed C., Farrugia A., et al. Comparison of the risk of viral infection between the living and nonliving musculoskeletal tissue donors in Australia. Transpl Int 2008, 21(10):936-941.
26. Zou S., Dodd R.Y., Stramer S.L., et al. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 2004, 351(8):751-759.
27. Lefrere J.J., Sellami F., Larderie P., et al. Six years' experience testing organ donors for viral markers in France. Transfusion 1997, 37(5):565-566.
28. Yeom J.S., Lee J.B., Ryu S.H., et al. Evaluation of a new third-generation ELISA for the detection of HIV infection. Ann Clin Lab Sci 2006, 36(1):73-78.
29. Louie B., Pandori M.W., Wong E., et al. Use of an acute seroconversion panel to evaluate a third-generation enzyme-linked immunoassay for detection of human immunodeficiency virus-specific antibodies relative to multiple other assays. J Clin Microbiol 2006, 44(5):1856-1858.
30. Yilmaz G. Diagnosis of HIV infection and laboratory monitoring of its therapy. J Clin Virol 2001, 21(3):187-196.
31. Yeom J.S., Jun G., Chang Y., et al. Evaluation of a new fourth generation enzyme-linked immunosorbent assay, the Ig HIV Ag-Ab plus, with a combined HIV p24 antigen and anti-HIV-1/2/o screening test. J Virol Methods 2006, 137(2):292-297.
32. Kwon J.A., Yoon S.Y., Lee C.K., et al. Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays. J Virol Methods 2006, 133(1):20-26.
33. Kleinman S. Blood donor screening with nucleic acid amplification tests for human immunodeficiency virus, hepatitis C virus, and hepatitis B virus. ISBT Sci Series 2008, 3:191-195.
34. Tobler L.H., Stramer S.L., Lee S.R., et al. Performance of ortho HCV core antigen and TRAK-c assays for detection of viraemia in pre-seroconversion plasma and whole blood donors. Vox Sang 2005, 89(4):201-207.
35. Simone A.G., David J.W., Steven H.K., et al. Dynamics of viremia in early hepatitis C virus infection. Transfusion 2005, 45(6):994-1002.
36. Stramer S.L. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med 2007, 131(5):702-707.
37. Part 1270. Human tissue intended for transplantation Available at:, Accessed March 15, 2010. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=1270.
38. Caliendo A. HIV, HCV, HBC NAT for organ donors 2009, Laboratory Issues, Chicago.
39. Abouna G.M. Organ shortage crisis: problems and possible solutions. Transplant Proc 2008, 40(1):34-38.
40. Chagas disease after organ transplantation-United States, 2001. MMWR Morb Mortal Wkly Rep 2002, 51(10):210-212.
41. Chagas disease after organ transplantation-Los Angeles, California, 2006. MMWR Morb Mortal Wkly Rep 2006, 55(29):798-800.
42. Pasternak J., Amato Neto V., Hammerschlack N. Chagas' disease after bone marrow transplantation. Bone Marrow Transplant 1997, 19(9):958.
43. Villalba R., Fornes G., Alvarez M.A., et al. Acute Chagas' disease in a recipient of a bone marrow transplant in Spain: case report. Clin Infect Dis 1992, 14(2):594-595.
44. Kun H., Moore A., Mascola L., et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 2009, 48(11):1534-1540.
45. Altclas J., Sinagra A., Dictar M., et al. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant 2005, 36(2):123-129.
46. Bern C., Montgomery S.P., Herwaldt B.L., et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 2007, 298(18):2171-2181.
47. Leiby D.A., Herron R.M., Garratty G., et al. Trypanosoma cruzi parasitemia in US blood donors with serologic evidence of infection. J Infect Dis 2008, 198(4):609-613.
48. Appleman M.D., Shulman I.A., Saxena S., et al. Use of a questionnaire to identify potential blood donors at risk for infection with Trypanosoma cruzi. Transfusion 1993, 33(1):61-64.
49. O'Brien S.F., Chiavetta J.A., Fan W., et al. Assessment of a travel question to identify donors with risk of Trypanosoma cruzi: operational validity and field testing. Transfusion 2008, 48(4):755-761.
50. Leiby D.A., Read E.J., Lenes B.A., et al. Seroepidemiology of Trypanosoma cruzi, etiologic agent of Chagas' disease, in US blood donors. J Infect Dis 1997, 176(4):1047-1052.
51. Nowicki M.J., Chinchilla C., Corado L., et al. Prevalence of antibodies to Trypanosoma cruzi among solid organ donors in southern California: a population at risk. Transplantation 2006, 81(3):477-479.
52. Leiby D.A., Herron R.M., Read E.J., et al. Trypanosoma cruzi in Los Angeles and Miami blood donors: impact of evolving donor demographics on seroprevalence and implications for transfusion transmission. Transfusion 2002, 42(5):549-555.
53. Bryan C.F., Tegtmeier G.E., Rafik N., et al. The risk for Chagas' disease in the midwestern United States organ donor population is low. Clin Transplant 2004, 18(Suppl 12):12-15.
54. Souza F.F., Castro E.S.O., Marin Neto J.A., et al. Acute chagasic myocardiopathy after orthotopic liver transplantation with donor and recipient serologically negative for Trypanosoma cruzi: a case report. Transplant Proc 2008, 40(3):875-878.
55. West Nile virus infection in organ donor and transplant recipients-Georgia and Florida, 2002. MMWR Morb Mortal Wkly Rep 2002, 51(35):790.
56. West Nile virus infections in organ transplant recipients-New York and Pennsylvania, August-September, 2005. MMWR Morb Mortal Wkly Rep 2005, 54(40):1021-1023.
57. Detection of West Nile virus in blood donations-Puerto Rico, 2007. MMWR Morb Mortal Wkly Rep 2008, 57(21):577-580.
58. Use of nucleic acid tests to reduce the risk of transmission of West Nile virus from donors of whole blood and blood components intended for transfusion and donors of human cells, tissues, and cellular and tissue-based products (HCT-Ps) Available at:, Accessed March 15, 2010. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/ucm078614.pdf.
59. Macedo de Oliveira A., Beecham B.D., Montgomery S.P., et al. West Nile virus blood transfusion-related infection despite nucleic acid testing. Transfusion 2004, 44(12):1695-1699.
60. Update: West Nile virus screening of blood donations and transfusion-associated transmission-United States, 2003. MMWR Morb Mortal Wkly Rep 2004, 53(13):281-284.
61. West Nile virus transmission through blood transfusion-South Dakota, 2006. MMWR Morb Mortal Wkly Rep 2007, 56(4):76-79.
62. Zhang W., Wu J., Li Y., et al. Rapid and accurate in vitro assays for detection of West Nile virus in blood and tissues. Transfus Med Rev 2009, 23(2):146-154.
63. Jazrawi A., Jones M., Kfoury A.G., et al. Tuberculosis in a solid-organ transplant recipient: modern-day implications. J Heart Lung Transplant 2009, 28(2):191-193.
64. Manuel O., Humar A., Preiksaitis J., et al. Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007, 7(12):2797-2801.
65. Lindemann M., Dioury Y., Beckebaum S., et al. Diagnosis of tuberculosis infection in patients awaiting liver transplantation. Hum Immunol 2009, 70(1):24-28.
66. Patel G., Arvelakis A., Sauter B.V., et al. Strongyloides hyperinfection syndrome after intestinal transplantation. Transpl Infect Dis 2008, 10(2):137-141.
67. Lichtenberger P., Rosa-Cunha I., Morris M., et al. Hyperinfection strongyloidiasis in a liver transplant recipient treated with parenteral ivermectin. Transpl Infect Dis 2009, 11(2):137-142.
68. Stone W.J., Schaffner W. Strongyloides infections in transplant recipients. Semin Respir Infect 1990, 5(1):58-64.
69. Martin-Davila P., Fortun J., Lopez-Velez R., et al. Transmission of tropical and geographically restricted infections during solid-organ transplantation. Clin Microbiol Rev 2008, 21(1):60-96.
70. Avery R.K. Recipient screening prior to solid-organ transplantation. Clin Infect Dis 2002, 35(12):1513-1519.
71. Derouin F., Pelloux H. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect 2008, 14(12):1089-1101.
72. Campbell A.L., Goldberg C.L., Magid M.S., et al. First case of toxoplasmosis following small bowel transplantation and systematic review of tissue-invasive toxoplasmosis following noncardiac solid organ transplantation. Transplantation 2006, 81(3):408-417.
73. Mayes J.T., O'Connor B.J., Avery R., et al. Transmission of Toxoplasma gondii infection by liver transplantation. Clin Infect Dis 1995, 21(3):511-515.
74. Barcan L.A., Dallurzo M.L., Clara L.O., et al. Toxoplasma gondii pneumonia in liver transplantation: survival after a severe case of reactivation. Transpl Infect Dis 2002, 4(2):93-96.
75. Gourishankar S., Doucette K., Fenton J., et al. The use of donor and recipient screening for Toxoplasma in the era of universal trimethoprim sulfamethoxazole prophylaxis. Transplantation 2008, 85(7):980-985.
76. Hermanns B., Brunn A., Schwarz E.R., et al. Fulminant toxoplasmosis in a heart transplant recipient. Pathol Res Pract 2001, 197(3):211-215.
77. Blair J.E., Mulligan D.C. Coccidioidomycosis in healthy persons evaluated for liver or kidney donation. Transpl Infect Dis 2007, 9(1):78-82.
78. Blair J.E. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species. Curr Opin Infect Dis 2008, 21(4):415-420.
79. Braddy C.M., Heilman R.L., Blair J.E. Coccidioidomycosis after renal transplantation in an endemic area. Am J Transplant 2006, 6(2):340-345.
80. Chung R.T., Feng S., Delmonico F.L. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001, 1(2):185-191.
81. Wolf J.L., Perkins H.A., Schreeder M.T., et al. The transplanted kidney as a source of hepatitis B infection. Ann Intern Med 1979, 91(3):412-413.
82. Wachs M.E., Amend W.J., Ascher N.L., et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995, 59(2):230-234.
83. Fong T.L., Bunnapradist S., Jordan S.C., et al. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of United Network of Organ Sharing database between 1994 and 1999. Transplantation 2002, 73(1):85-89.
84. Tur-Kaspa R., Burk R.D., Shaul Y., et al. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A 1986, 83(6):1627-1631.
85. Jiang H., Wu J., Zhang X., et al. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center. Am J Transplant 2009, 9(8):1853-1858.
86. Fishman J.A., Rubin R.H., Koziel M.J., et al. Hepatitis C virus and organ transplantation. Transplantation 1996, 62(2):147-154.
87. Candinas D., Joller-Jemelka H.I., Schlumpf R., et al. Hepatitis C RNA prevalence in a western European organ donor pool and virus transmission by organ transplantation. J Med Microbiol 1994, 41(4):220-223.
88. Vargas H.E., Laskus T., Wang L.F., et al. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg 1998, 4(1):22-27.
89. Ali M.K., Light J.A., Barhyte D.Y., et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation 1998, 66(12):1694-1697.
90. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. MMWR Recomm Rep 1994, 43(RR-8):1-17.
91. Ison M.G., Friedewald J.J. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl 2009, 15(5):561. [author reply: 62].